title: Tipranavir favored in RESIST-2.
mesh_terms: D001315:Australia; D002170:Canada; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D011725:Pyridines / Q000008:administration & dosage* / Q000009:adverse effects; D011753:Pyrones / Q000008:administration & dosage* / Q000009:adverse effects; D018570:Risk Assessment; D012720:Severity of Illness Index; D013449:Sulfonamides; D016896:Treatment Outcome; D014481:United States; D019562:Viral Load
chemical_list: D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; C107201:tipranavir